A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2022-09-09 / Cancer Immunol Immunother 2023 Apr;72(4):827-840Dendritic-Cell-Vaccine-Based Immunotherapy for Hepatocellular Carcinoma: Clinical Trials and Recent Preclinical Studies
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2022-09-08 / Cancers (Basel) 2022 Sep;14(18)Current and emerging immunotherapeutic approaches for biliary tract cancers
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2022-09-07 / Hepatobiliary Pancreat Dis Int 2022 Oct;21(5):440-449Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
/in Brain Tumors in Children, Dendritic Cells, Immunogenic Cell Death, International Publications, Newcastle Disease Virus /von 2022-08-24 / Pharmaceutics 2022 Aug;14(9)Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2022-08-21 / Cancers (Basel) 2022 Aug;14(16)Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities
/in Dendritic Cells, International Publications /von 2022-08-10 / Immunol Invest 2022 Nov;51(8):2133-2158Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
/in Breast Cancer, Dendritic Cells, International Publications /von 2022-08-03 / J Control Release 2022 Sep;349:844-875Triiodothyronine-stimulated dendritic cell vaccination boosts antitumor immunity against murine colon cancer
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2022-08-01 / Int Immunopharmacol 2022 Sep;110:109016Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2022-07-25 / Epigenomics 2022 Jul;14(14):865-886
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de